ACOG updated treatment for bacterial vaginosis and Recurrent BV
Reading File
Finding Sources
Searching PubMed
"bacterial vaginosis" AND treatment
Searching the Web
ACOG bacterial vaginosis treatment guidelines 2024 2025 recurrent BV
Reading Web Page
ACOG bacterial vaginosis treatment recurrent BV guidelines recommendations
Reading File
Searching PubMed
"bacterial vaginosis" AND "partner treatment" AND recurrent
Reading Article
Searching the Web
ACOG Clinical Practice Update bacterial vaginosis October 2025 treatment regimens secnidazole LACTIN-V suppressive
Reading Web Page
bacterial vaginosis treatment regimens recurrent suppressive therapy LACTIN-V secnidazole partner treatment
I now have comprehensive data to provide a detailed, well-sourced answer. Here is the full synthesis:
ACOG Updated Guidance on Bacterial Vaginosis (BV) Treatment
Published: October 16, 2025 (print: December 2025)
Document: ACOG Clinical Practice Update - "Concurrent Sexual Partner Therapy to Prevent Bacterial Vaginosis Recurrence" (Obstet Gynecol 2025;146:e111-e114)
Updates: Practice Bulletin No. 215, Vaginitis in Nonpregnant Patients (2020)
The Core Change: Sexual Partner Therapy
This is the most significant shift in ACOG's BV guidance. Previously, BV was not considered an STI and partner treatment was not recommended - a 2016 Cochrane review found no clear benefit from treating male partners. New data reversed this position.
What Drove the Change
The landmark trial was the StepUp RCT (Vodstrcil et al., NEJM 2025; PMID: 40043236):
- Design: Open-label, multicenter Phase III RCT in 164 couples (monogamous, woman with BV + male partner)
- The trial was stopped early by the data safety monitoring board because standard-care-only arm was clearly inferior
- Results: Recurrence at 12 weeks was 35% with partner treatment vs. 63% without (absolute risk difference: -2.6 recurrences/person-year, P<0.001)
- Best outcomes were seen when male partners had 100% adherence (recurrence rate 1.3/person-year)
Updated ACOG Clinical Recommendations
1. Recurrent, Symptomatic BV with a Male Partner (STRONG recommendation)
Concurrent sexual partner therapy SHOULD BE CONSIDERED using a combination of:
- Oral metronidazole 400 mg twice daily x 7 days (for male partner)
- 2% clindamycin cream applied topically to penile skin twice daily x 7 days (for male partner)
- Male partner adverse effects: nausea, headache, metallic taste
2. Recurrent Symptomatic BV with a Same-Sex Partner (Shared Decision-Making)
- Shared decision-making regarding partner therapy is recommended
- Evidence is more limited for same-sex couples; the StepUp trial enrolled only male-female couples
3. First Occurrence of Symptomatic BV (Shared Decision-Making)
- Shared decision-making about partner therapy is also recommended even at first presentation
4. Abstinence During Treatment
- Both partners should abstain during the 7-day treatment period, or the male partner should use condoms to reduce reinfection risk
5. Partners Outside Monogamy / Prior Partners
- No data for non-monogamous relationships - shared decision-making applies
- No indication to treat prior/past partners (goal is preventing ongoing recurrence)
Standard BV Treatment Regimens (Unchanged)
These remain per CDC 2021 STI Guidelines and ACOG Practice Bulletin 215:
First-Line (Recommended)
| Regimen | Dose |
|---|---|
| Metronidazole oral | 500 mg twice daily x 7 days |
| Metronidazole gel 0.75% | 5 g intravaginally once daily x 5 days |
| Clindamycin cream 2% | 5 g intravaginally at bedtime x 7 days |
Alternative Regimens
| Regimen | Dose |
|---|---|
| Secnidazole | 2 g oral single dose (FDA approved 2017) |
| Tinidazole | 1 g daily x 5 days OR 2 g daily x 3 days |
| Clindamycin oral | 300 mg twice daily x 7 days |
| Clindamycin ovules | 100 mg intravaginally once at bedtime x 3 days |
| Clindamycin vaginal gel (single-dose) | FDA approved 2021 |
Harrison's Principles of Internal Medicine 22E (2025), p. 1049
Recurrent BV: Suppressive Strategies
Up to 66% of women experience recurrence within 12 months of initial treatment. Strategies include:
Suppressive Antimicrobial Therapy
- Twice-weekly intravaginal metronidazole gel (0.75%) - significantly reduces recurrences (Sobel et al., 2006); note that the 37.5 mg/dose preparation has higher recurrence rates than 500 mg suppositories, suggesting higher intravaginal doses matter
Probiotics / Microbiome Restoration
- LACTIN-V (L. crispatus CTV-05) - weekly vaginal administration reduced recurrent BV by approximately one-third in a randomized trial (Harrison's 22E, 2025)
- A 2025 systematic review (PMID: 40352249) confirms that specific probiotic regimens can reduce BV recurrence and support treatment
Duration of Suppressive Therapy
- In some cases, 3-6 months of maintenance treatment may be required
Key Practical Points
- Insurance coverage: Sexual partner therapy for BV may not be covered - counsel patients upfront about potential out-of-pocket costs
- Partner adherence matters: Recurrence benefit was strongest when male partners had 100% adherence to both oral and topical agents
- STI framing: Evidence increasingly supports sexual activity as a transmission pathway for BV-associated organisms, even though BV is not formally classified as an STI
- Pregnant patients: ACOG's update applies to nonpregnant patients; the 2020 Practice Bulletin guidance for pregnancy remains in effect. Topical clindamycin is commonly used in pregnancy, but oral metronidazole data in pregnancy has been inconsistent and routine antenatal screening is not recommended by USPSTF
- Ongoing research gaps: Same-sex couples, non-monogamous relationships, asymptomatic BV - all need more inclusive data
Supporting Literature
- StepUp RCT, NEJM 2025 - Male-Partner Treatment to Prevent Recurrence of BV (PMID: 40043236)
- Network meta-analysis of BV drugs (PMID: 39463760, 2024)
- Tinidazole vs metronidazole systematic review (PMID: 39969560, 2025)
- Probiotics for BV prevention meta-analysis (PMID: 38802199, 2024)
- Harrison's Principles of Internal Medicine 22E (2025), p. 1049
Give in more concise form
ACOG BV Update - October 2025
Key Change: Sexual partner therapy now recommended for recurrent BV (updates Practice Bulletin 215, 2020)
What Changed: Partner Treatment
Driven by the StepUp RCT (NEJM 2025) - trial stopped early because results were so clear:
- Recurrence at 12 weeks: 35% (partner treated) vs. 63% (no partner treatment)
| Patient Situation | Recommendation |
|---|---|
| Recurrent BV + male partner | Consider concurrent partner therapy |
| Recurrent BV + same-sex partner | Shared decision-making |
| First-occurrence BV (any partner) | Shared decision-making |
Male partner regimen: Metronidazole 400 mg PO BID x 7 days + clindamycin 2% cream to penile skin BID x 7 days. Both partners abstain (or condom use) during treatment.
Standard BV Treatment (Unchanged)
First-line (any one of):
- Metronidazole 500 mg PO BID x 7 days
- Metronidazole gel 0.75% intravaginally x 5 days
- Clindamycin cream 2% intravaginally x 7 days
Alternatives: Secnidazole 2 g PO single dose | Tinidazole 1-2 g/day x 3-5 days | Clindamycin PO 300 mg BID x 7 days
Recurrent BV Suppression
- Metronidazole gel 0.75% twice weekly (maintenance)
- LACTIN-V (L. crispatus CTV-05) weekly vaginally - reduces recurrence by ~1/3
- Suppressive therapy duration: up to 3-6 months
- Up to 66% of women relapse within 12 months of initial treatment
Key Caveats
- Applies to nonpregnant patients only
- Insurance may not cover partner therapy - counsel patients
- No data yet for non-monogamous relationships or asymptomatic BV
This is a shared conversation. Sign in to Orris to start your own chat.